Kalydeco Europäische Union - Deutsch - EMA (European Medicines Agency)

kalydeco

vertex pharmaceuticals (ireland) limited - ivacaftor - mukoviszidose - andere produkte für die atemwege - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 und 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 und 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Orkambi Europäische Union - Deutsch - EMA (European Medicines Agency)

orkambi

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - mukoviszidose - andere produkte für die atemwege - orkambi tabletten sind angezeigt für die behandlung von zystischer fibrose (cf) bei patienten im alter von 6 jahren und älter, die homozygot für die f508del-mutation im cftr-gen. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Memigmin Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

memigmin

egis pharmaceuticals private limited company (3332760) - memantinhydrochlorid - filmtablette - teil 1 - filmtablette; memantinhydrochlorid (16705) 10 milligramm

Tadalafil APL 20 mg Filmtabletten Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

tadalafil apl 20 mg filmtabletten

alembic pharmaceuticals europe limited (8146921) - tadalafil; tadalafil - filmtablette - tadalafil (29976) 18,5 milligramm; tadalafil (29976) 1,5 milligramm

Symkevi Europäische Union - Deutsch - EMA (European Medicines Agency)

symkevi

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - mukoviszidose - andere produkte für die atemwege - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Quetiapine Intas Pharmaceuticals 50 mg Retardtablette Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

quetiapine intas pharmaceuticals 50 mg retardtablette

intas pharmaceuticals - quetiapine fumarate - retardtablette - 50 mg - quetiapine fumarate 57.575 mg - quetiapine

Quetiapine Intas Pharmaceuticals 200 mg Retardtablette Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

quetiapine intas pharmaceuticals 200 mg retardtablette

intas pharmaceuticals - quetiapine fumarate - retardtablette - 200 mg - quetiapine fumarate 230.3 mg - quetiapine

Quetiapine Intas Pharmaceuticals 300 mg Retardtablette Belgien - Deutsch - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

quetiapine intas pharmaceuticals 300 mg retardtablette

intas pharmaceuticals - quetiapine fumarate - retardtablette - 300 mg - quetiapine fumarate 345.45 mg - quetiapine